| Literature DB >> 28579687 |
Karthik M Sundaram1, Sam S Chang2, David F Penson2, Sandeep Arora1,2.
Abstract
Therapeutic ultrasound approaches including high-intensity focused ultrasound (HIFU) are emerging as popular minimally invasive alternative treatments for localized, low-to-intermediate risk prostate cancer. FDA approval was recently granted for two ultrasound-guided HIFU devices. Clinical trials for devices using MRI guidance are ongoing. The current level of evidence for whole-gland ultrasound ablation suggests that its clinical efficacy and adverse event rates including erectile dysfunction and urinary incontinence are similar to current definitive therapies such as radical prostatectomy and external-beam radiotherapy. Short-term data suggest that more focal therapy could reduce the rates of adverse events.Entities:
Keywords: high-intensity directional ultrasound; high-intensity focused ultrasound; prostate cancer; therapeutic ultrasound
Year: 2017 PMID: 28579687 PMCID: PMC5453783 DOI: 10.1055/s-0037-1602710
Source DB: PubMed Journal: Semin Intervent Radiol ISSN: 0739-9529 Impact factor: 1.513